Preclinical results support entinostat’s role in targeting the tumor microenvironment

A preclinical report demonstrates that entinostat, Syndax’s oral, Class-I histone deacetylase inhibitor, enhances the antitumor effect of PD-1 (programmed death receptor-1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).